Pirtobrutinib plus BEAM before stem cell transplant for lymphoma
This trial is testing a new treatment for people with a type of lymphoma (DLBCL) that has not gone away or has come back. It combines a study drug called pirtobrutinib with a common chemotherapy regimen (BEAM) before a stem cell transplant, and the goal is to see if this approach is safe and effective in helping patients get to transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with DLBCL that has returned or not improved after at least two rounds of standard treatment.
- Your doctor has confirmed that your cancer is in partial or complete remission after this treatment.
- You have not had a stem cell transplant in the past.
- Your overall health is good enough, with normal heart, liver, and kidney function.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding zanubrutinib to standard high-dose chemotherapy (BEAM) before a stem cell transplant for people with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if this combination helps control the lymphoma better before the transplant.
This trial tests a new targeted therapy (pirtobrutinib) added to standard chemotherapy for a specific type of lymphoma. It aims to see if the combination improves outcomes for patients who have not been treated before.
This trial tests adding selinexor to a standard chemotherapy regimen (BEAM) before a stem cell transplant for people with a certain type of large B-cell lymphoma that has MYC positive. It aims to see if this combination can improve outcomes.
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to the standard BEAM chemotherapy before a stem cell transplant can help people with relapsed Hodgkin lymphoma. It's for patients who are eligible for a transplant and have stable organ function.
This trial tests a new combination of drugs for a certain type of lymphoma (non-GCB DLBCL). The drugs are pirtobrutinib (a targeted pill) plus a standard chemotherapy regimen called Pola-R-CHP. The goal is to see if adding this targeted therapy improves outcomes for people with this specific subtype.
This Phase 3 study compares two chemotherapy schedules (Chi-BEAM vs BEAM) given before an autologous stem cell transplant to treat newly diagnosed peripheral T-cell lymphoma that responded to first-line treatment. If you fit the lab and heart/lung requirements, it may offer access to a new treatment approach designed to improve outcomes.
Hear when a new DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.